Download PDF
Endoscopy 2017; 49(01): 27-34
DOI: 10.1055/s-0042-119402
Original article
© Georg Thieme Verlag KG Stuttgart · New York

Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study

Wouter F. W. Kappelle
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Gerlof D. Valk
2   Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Max Leenders
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Leon M. G. Moons
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Auke Bogte
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Peter D. Siersema
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
,
Frank P. Vleggaar
1   Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

submitted 22 June 2016

accepted after revision 26 September 2016

Publication Date:
14 December 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Background and aims In multiple endocrine neoplasia type 1 (MEN1), endoscopic ultrasound (EUS) is used for identification and follow-up of pancreatic neuroendocrine tumors (PNETs). The role of EUS in surveillance of small ( < 20 mm) PNETs is unclear, mostly because the natural course of these lesions is largely unknown. We aimed to determine annual growth and incidence rate of small PNETs in patients with MEN1 using EUS-based surveillance.

Patients and methods Linear array EUS procedures in patients with MEN1 between 2002 and 2015 were identified. Number, size, and location of PNETs were recorded. Annual growth of PNETs < 20 mm identified at the initial EUS (“prevalent” PNETs) and during follow-up (“incident” PNETs) was calculated using mixed model linear regression analysis.

Results A total of 54 patients were identified and 38 patients were included. In all, 226 PNETs were identified (median size 5.0 mm, interquartile range 3.7 – 7.5) of which 124 (55 %) were prevalent and 102 (45 %) were incident PNETs. Annual incidence rate was 0.79 PNETs/year (95 % confidence interval [CI] 0.73 to 0.87). Overall growth rate was 0.10 mm/year (95 %CI 0.02 to 0.19; P = 0.01); PNETs < 10 mm (n = 198) did not grow (P = 0.23), whereas PNETs ≥ 10 mm (n = 28) grew 0.44 mm/year (95 %CI 0.10 to 0.78; P = 0.01). Prevalent PNETs grew 0.21 mm/year (95 %CI 0.10 – 0.32; P < 0.001), whereas incident PNETs did not grow (P = 0.26).

Conclusions The annual growth rate of small, solid PNETs in patients with MEN1 is lower than previously thought. Surveillance intervals could probably be prolonged without compromising safety.

 

  • References

  • 1 Sadowski SM, Triponez F. Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surgery 2015; 4: 63-68
    PubMedGoogle Scholar
  • 2 Goudet P, Murat A, Binquet C. et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34: 249-255
    CrossrefPubMedGoogle Scholar
  • 3 Walls GV. Multiple endocrine neoplasia (MEN) syndromes. Semin Pediatr Surg 2014; 23: 96-101
    CrossrefPubMedGoogle Scholar
  • 4 van Asselt SJ, Brouwers AH, van Dullemen HM. et al. EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1. Gastrointest Endosc 2015; 81: 159-167
    CrossrefPubMedGoogle Scholar
  • 5 Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492
    CrossrefPubMedGoogle Scholar
  • 6 Pieterman CR, Conemans EB, Dreijerink KM. et al. Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis. Endocr Relat Cancer 2014; 21: R121-142
    CrossrefPubMedGoogle Scholar
  • 7 Dean PG, van Heerden JA, Farley DR. et al. Are patients with multiple endocrine neoplasia type I prone to premature death?. World J Surg 2000; 24: 1437-1441
    CrossrefPubMedGoogle Scholar
  • 8 Pieterman CR, Schreinemakers JM, Koppeschaar HP. et al. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome. Clin Endocrinol 2009; 70: 575-581
    CrossrefPubMedGoogle Scholar
  • 9 Hellman P, Hennings J, Akerstrom G. et al. Endoscopic ultrasonography for evaluation of pancreatic tumours in multiple endocrine neoplasia type 1. Br J Surg 2005; 92: 1508-1512
    CrossrefPubMedGoogle Scholar
  • 10 Lewis MA, Thompson GB, Young Jr WF. Preoperative assessment of the pancreas in multiple endocrine neoplasia type 1. World J Surg 2012; 36: 1375-1381
    CrossrefPubMedGoogle Scholar
  • 11 Thakker RV, Newey PJ, Walls GV. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011
    CrossrefPubMedGoogle Scholar
  • 12 Bettini R, Partelli S, Boninsegna L. et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 2011; 150: 75-82
    CrossrefPubMedGoogle Scholar
  • 13 Falconi M, Bartsch DK, Eriksson B. et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 2012; 95: 120-134
    CrossrefPubMedGoogle Scholar
  • 14 Kulke MH, Anthony LB, Bushnell DL. et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 735-752
    CrossrefPubMedGoogle Scholar
  • 15 Triponez F, Goudet P, Dosseh D. et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654-662
    CrossrefPubMedGoogle Scholar
  • 16 Kann PH, Kann B, Fassbender WJ. et al. Small neuroendocrine pancreatic tumors in multiple endocrine neoplasia type 1 (MEN1): least significant change of tumor diameter as determined by endoscopic ultrasound (EUS) imaging. Exp Clin Endocrinol Diabetes 2006; 114: 361-365
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Kann PH, Balakina E, Ivan D. et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer 2006; 13: 1195-1202
    CrossrefPubMedGoogle Scholar
  • 18 D’souza SL, Elmunzer BJ, Scheiman JM. Long-term follow-up of asymptomatic pancreatic neuroendocrine tumors in multiple endocrine neoplasia type I syndrome. J Clin Gastroenterol 2014; 48: 458-461
    PubMedGoogle Scholar
  • 19 Barbe C, Murat A, Dupas B. et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis 2012; 44: 228-234
    CrossrefPubMedGoogle Scholar
  • 20 Langer P, Kann PH, Fendrich V. et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg 2004; 28: 1317-1322
    CrossrefPubMedGoogle Scholar
  • 21 Gauger PG, Scheiman JM, Wamsteker EJ. et al. Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumours in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg 2003; 90: 748-754
    CrossrefPubMedGoogle Scholar
  • 22 Anlauf M, Schlenger R, Perren A. et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006; 30: 560-574
    CrossrefPubMedGoogle Scholar
  • 23 Gauger PG, Doherty GM, Broome JT. et al. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 2009; 146: 801-808
    CrossrefPubMedGoogle Scholar
  • 24 Thomas-Marques L, Murat A, Delemer B. et al. Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006; 101: 266-273
    CrossrefPubMedGoogle Scholar
  • 25 Pieterman CR, de Laat JM, Twisk JW. et al. Growth rate of MEN1-related pancreatic neuroendocrine tumors: new insights based on the results from the DutchMEN1 Study Group (DMSG) National MEN1 Database 1990–2010. Abstract presented at Endocrine Society’s 97th Annual Meeting and Expo; 2015 March 5–8; San Diego, California. Endocrine Reviews 2015; 36: 2-3 Available from http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2015.TB.2.PP02-3 Accessed: 12 May 2016
    PubMedGoogle Scholar
  • 26 Sakurai A, Katai M, Yamashita K. et al. Long-term follow-up of patients with multiple endocrine neoplasia type 1. Endocr J 2007; 54: 295-302
    CrossrefPubMedGoogle Scholar
  • 27 Skogseid B. Multiple endocrine neoplasia type 1. Br J Surg 2003; 90: 383-385
    CrossrefPubMedGoogle Scholar
  • 28 Toste PA, Kadera BE, Tatishchev SF. et al. Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival. J Gastrointest Surg 2013; 17: 2105-2113
    CrossrefPubMedGoogle Scholar
  • 29 Haynes AB, Deshpande V, Ingkakul T. et al. Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes. Arch Surg 2011; 146: 534-538
    CrossrefPubMedGoogle Scholar